Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
-1.72%
)
Bitcoin
70,222.64
(
-0.42%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: DewDiligence post# 130474

Monday, 11/07/2011 11:14:44 PM

Monday, November 07, 2011 11:14:44 PM

Post# of 257268

BMY reports interim phase-2 data for all-oral regimen of BMS-790052 plus BMS-650032

Side effects aside, this data would appear to back up ACHN's prior assertions (item 3 of #msg-66070779 ) about an NS5A + PI potentially being enough for genotype 1b patients.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today